[go: up one dir, main page]

EA200900802A1 - Способы и композиции для лечения амилоидных заболеваний - Google Patents

Способы и композиции для лечения амилоидных заболеваний

Info

Publication number
EA200900802A1
EA200900802A1 EA200900802A EA200900802A EA200900802A1 EA 200900802 A1 EA200900802 A1 EA 200900802A1 EA 200900802 A EA200900802 A EA 200900802A EA 200900802 A EA200900802 A EA 200900802A EA 200900802 A1 EA200900802 A1 EA 200900802A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
treatment
amyloid diseases
diseases
Prior art date
Application number
EA200900802A
Other languages
English (en)
Other versions
EA019334B1 (ru
Inventor
Ксианки Конг
Дэвид Мигнол
Изабелль Валяд
Ксинфу Ву
Франсин Жерве
Original Assignee
Беллус Хелс (Интернэшнл) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Application filed by Беллус Хелс (Интернэшнл) Лимитед filed Critical Беллус Хелс (Интернэшнл) Лимитед
Publication of EA200900802A1 publication Critical patent/EA200900802A1/ru
Publication of EA019334B1 publication Critical patent/EA019334B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/69—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/02—Thiosulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описаны способы, соединения, фармацевтические композиции и наборы для лечения или предупреждения амилоидных заболеваний.
EA200900802A 2003-06-23 2004-06-21 Способы и композиции для лечения амилоидных заболеваний EA019334B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48090603P 2003-06-23 2003-06-23
US51204703P 2003-10-17 2003-10-17
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases

Publications (2)

Publication Number Publication Date
EA200900802A1 true EA200900802A1 (ru) 2010-04-30
EA019334B1 EA019334B1 (ru) 2014-02-28

Family

ID=34139588

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900802A EA019334B1 (ru) 2003-06-23 2004-06-21 Способы и композиции для лечения амилоидных заболеваний

Country Status (6)

Country Link
US (3) US7244764B2 (ru)
CN (1) CN101712640A (ru)
EA (1) EA019334B1 (ru)
IL (1) IL172194A (ru)
NZ (1) NZ579241A (ru)
TW (2) TW200520752A (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
MXPA01010835A (es) * 1999-04-28 2003-07-14 Univ Kingston Composiciones y metodos para tratar amiloidosis.
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US7420071B2 (en) * 2005-05-04 2008-09-02 Uchicago Argonne, Llc Thermally stable surfactants and compositions and methods of use thereof
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
ES2533463T3 (es) 2006-10-12 2015-04-10 Bhi Limited Partnership Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
US20080262088A1 (en) * 2006-12-22 2008-10-23 Wendy Hauck Methods, compounds, and compositions for treating metabolic disorders and diabetes
CN102016059B (zh) * 2007-12-28 2014-10-22 依兰制药公司 淀粉样变性的治疗和预防
US20110237646A1 (en) * 2008-08-07 2011-09-29 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression for the treatment of cns related disorders
EA201170422A1 (ru) * 2008-11-14 2011-10-31 Беллус Хелс Инк. Органические соли питательных веществ, способы получения и применения
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
KR20180026798A (ko) 2010-04-29 2018-03-13 아이오니스 파마수티컬즈, 인코포레이티드 트랜스티레틴 발현의 조절
WO2011140333A1 (en) * 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
RU2466986C1 (ru) * 2011-05-30 2012-11-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран Способ получения n,n,-дизамещенных n-{[алкил(бензил)сульфанил]метил}аминов
CN103874496A (zh) 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
EP3718547A1 (en) 2011-10-03 2020-10-07 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CA2894919A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. C5,c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014099788A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
EP2968356B1 (en) 2013-03-15 2018-03-07 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiadiazine compounds as bace inhibitors, compositions, and their use
WO2014150344A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as bace inhibitors
EP2968357B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
EP3082823B1 (en) 2013-12-18 2020-04-22 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use
WO2015094930A1 (en) 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. C-6 spirocarbocyclic iminothiadiazine dioxides as bace inhibitors, compositions, and their use
EP3148996B1 (en) 2014-06-02 2021-05-05 Merck Sharp & Dohme Corp. C2-carbocyclic iminothiazine dioxides as bace inhibitors, compositions, and their use
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
EP3201204B1 (en) 2014-10-03 2021-02-24 Merck Sharp & Dohme Corp. C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP3223820B1 (en) 2014-11-25 2020-07-22 Merck Sharp & Dohme Corp. 3-methyl-2-imino-hexahydro-1h-pyrano[3,4-d]pyrimidin-4-one compounds as bace inhibitors, compositions, and their use
US10071998B2 (en) 2015-01-20 2018-09-11 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides bearing an amine-linked substituent as BACE inhibitors, compositions, and their use
CN107530389B (zh) 2015-02-27 2021-10-26 考格尼克拉瑞提公司 用于在人和动物中处理“斑和缠结”的组合物和方法
WO2017027582A1 (en) * 2015-08-10 2017-02-16 Alzheon, Inc. Compositions and methods for treating and preventing neurodegenerative disorders
WO2017139209A1 (en) 2016-02-11 2017-08-17 Merck Sharp & Dohme Corp. C5-c6-oxacylic fused iminothiazine dioxide compounds bearing an ether linker as bace inhibitors, compositions, and their use
CN106674063A (zh) * 2016-12-21 2017-05-17 中国科学院兰州化学物理研究所 两性有机小分子凝胶因子及其制备方法和应用
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
MX2020003608A (es) * 2017-09-29 2020-09-25 Intellia Therapeutics Inc Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr.
US12419905B2 (en) 2018-07-06 2025-09-23 Yale University Methods and compositions for the treatment of amyloid-related disorders
CN109432045B (zh) * 2018-11-29 2021-11-23 佛山市正典生物技术有限公司 一种二氢吡啶微囊制剂及其制备方法
CA3122687A1 (en) 2018-12-12 2020-06-18 Cognitive Clarity Inc. Compositions and methods for the treatment of "plaques and tangles" in humans and animals
CN109824555B (zh) * 2019-01-30 2021-02-19 华南理工大学 一种氨基磺酸及其制备方法与应用

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531468A (en) 1949-04-14 1950-11-28 Eastman Kodak Co Polyvinyl sulfonates and process for their preparation
DE927992C (de) 1952-07-27 1955-05-23 Hoechst Ag Verfahren zur Herstellung von Salzen des 1, 2-Dimethyl-3-phenyl-4-amino-5-pyrazolons
DE1122064B (de) 1960-01-09 1962-01-18 Basf Ag Verfahren zur Einfuehrung von alyphatischen Kohlenwasserstoffresten in organische Verbindungen, die Hydroxylgruppen, tertiaere Aminogruppen, aromatische gebundene Sulfhydrylgruppen und bzw. oder aromatisch gebundene primaere oder sekundaere Aminogruppen enthalten
US3218352A (en) 1962-05-03 1965-11-16 Abbott Lab Homotaurine process
US3658966A (en) 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
DE2140278A1 (en) 1970-01-19 1972-03-09 Crompton and Knowles Corp., Worcester, Mass. (V.St.A.) Water-soluble dyes and dye intermediates
US3872125A (en) 1973-03-03 1975-03-18 Sandoz Ag 3-substituted-4-aryl isoquinolines
US4085134A (en) 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
US3920833A (en) 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
US4187245A (en) * 1975-06-02 1980-02-05 Petrolite Corporation Hydroxypropylene-amino-phosphonic-sulfonic acids
FR2384751A1 (fr) 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
CA1140049A (en) 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
FR2437834A1 (fr) 1978-10-04 1980-04-30 Lejeune Jerome Compositions pharmaceutiques a base de l-serine ou de glycine
FR2457281A1 (fr) 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4255448A (en) 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4448779A (en) 1981-07-16 1984-05-15 Sanofi Use of MS salt in geriatric medicine
JPS5879022A (ja) 1981-11-04 1983-05-12 Bitamin Kenkyusho:Kk 第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
FR2529546A1 (fr) 1982-07-05 1984-01-06 Meram Lab Nouveaux sels d'amino-(et imino-)acides a, o-sulfoniques n-substitues, vecteurs cationiques de haute penetration cellulaire
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1193590B (it) 1983-01-07 1988-07-08 Loris Jacopo Bononi Derivati amino-alchil-solfonici,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
US4737353A (en) 1984-04-13 1988-04-12 Union Carbide Corporation Beryllium-aluminum-phosphorus-silicon-oxide molecular sieve compositions
DE3438291A1 (de) 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JPH0733332B2 (ja) 1985-11-19 1995-04-12 富山化学工業株式会社 痴呆症状改善・治療剤
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2595356B1 (fr) 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
JPH0786122B2 (ja) 1986-05-30 1995-09-20 日本ペイント株式会社 三次元架橋された微小樹脂粒子およびその製造法
EP0278008B1 (en) * 1986-08-20 1993-01-20 Taiho Pharmaceutical Company Limited Taurine type compounds
US4919915A (en) 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US5039794A (en) 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
AU1790988A (en) 1987-05-19 1988-12-21 Baylor College Of Medicine Phosphoethanolamine for treatment of alzheimer's disease
IT1205042B (it) 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
IT1211792B (it) 1987-09-21 1989-11-03 Sigma Tau Ind Farmaceuti O-alcanoil derivati dell'acido 3ammino-2-idrossipropansolfonico adattivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia
AU2800689A (en) 1987-11-18 1989-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Differential delivery of therapeutic agents across the blood brain barrier
JPH01171638A (ja) 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
JP2587842B2 (ja) 1987-12-09 1997-03-05 株式会社ニチレイ 神経疾患治療・予防剤
DK505488D0 (da) 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4968678A (en) 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
ATE87918T1 (de) 1988-02-19 1993-04-15 Lilly Co Eli Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
AU3757789A (en) 1988-05-18 1989-12-12 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
JPH0627072B2 (ja) 1988-09-13 1994-04-13 呉羽化学工業株式会社 アミノ安息香酸誘導体を有効成分とする生体内抗酸化機構調節剤
JPH0667472B2 (ja) 1988-11-28 1994-08-31 鐘淵化学工業株式会社 血清アミロイドｐ蛋白用吸着体
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
JP2761048B2 (ja) 1989-08-25 1998-06-04 三共株式会社 神経成長因子産生促進剤
DK437289D0 (da) 1989-09-04 1989-09-04 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
EP0494175A4 (en) 1989-09-27 1993-05-05 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE3940410A1 (de) 1989-12-04 1991-06-06 Schering Ag Neue verwendung von nmda-rezeptor-antagonisten
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
DE4004978A1 (de) 1990-02-19 1991-08-22 Nmi Naturwissenschaftl U Mediz Praeventive therapie fuer morbus alzheimer
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
DE4021066A1 (de) 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
ATE150301T1 (de) 1990-07-19 1997-04-15 Nippon Zoki Pharmaceutical Co Aminoalkanesulfonsäurederivate und pharmazeutische zusammensetzungen davon zur prävention oder behandlung von herzerkrankungen
US5137873A (en) 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
MX9100993A (es) 1990-09-10 1992-05-04 Us Agriculture Secuencia de adn aislado y enzima acido 1-aminociclopropan-1-carboxilico sintasa,recombinante
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5270312A (en) 1990-11-05 1993-12-14 Warner-Lambert Company Substituted piperazines as central nervous system agents
JP2980749B2 (ja) 1990-11-30 1999-11-22 協和醗酵工業株式会社 フラン誘導体
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2104594C (en) 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
GB9117716D0 (en) 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
AU669493B2 (en) 1991-11-12 1996-06-13 University Of Melbourne, The A method for assaying and treating Alzheimer's disease
ES2096064T3 (es) 1991-12-19 1997-03-01 Ciba Geigy Ag Derivados del acido aminosulfonico y procedimiento para su obtencion.
US5318958A (en) * 1992-05-29 1994-06-07 Queen's University At Kingston Amyloid precursor protein
US6004936A (en) 1992-05-29 1999-12-21 Queen's University At Kingston Method of use of serum amyloid a protein
JP3295423B2 (ja) 1992-05-29 2002-06-24 ザ ユニバーシティ オブ ブリティッシュ コロンビア 痴呆の処置のためのダプソーン及びプロミン
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
EP0604641B1 (en) 1992-06-30 2002-03-20 SHAPIRO, Howard, K. Use of a combination containing an amine or amine-related derivative of benzoic acid and an amino-polysaccharide in the manufacture of a medicament for the treatment of inflammatory diseases
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
EP0607408A4 (en) 1992-07-13 1997-12-10 Eukarion Inc Transvascular and intracellular delivery of lipidized proteins.
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
DK0614886T3 (da) 1992-07-30 1997-01-13 Drug Delivery System Inst Ltd Forbindelser, der kan tilbageholdes i hjernen
US5383988A (en) 1992-09-10 1995-01-24 Paragon Trade Brands, Inc. Modular apparatus for fabricating an absorbent article
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5972328A (en) 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
ATE311864T1 (de) 1993-03-29 2005-12-15 Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosis
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
DE4313118A1 (de) 1993-04-22 1994-10-27 Hoechst Ag Verwendung von 1,2,3,4-Tetrahydroisochinolin-Derivaten als Antimykotika
US5434137A (en) 1993-05-10 1995-07-18 Black; Keith L. Method for selective opening of abnormal brain tissue capillaries
AU6836394A (en) 1993-06-01 1994-12-20 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
AU7642494A (en) 1993-08-31 1995-03-22 Gliatech Inc. Inhibition of beta amyloid binding to glycosaminoglycans for treatment of alzheimer's disease
WO1995007092A1 (en) 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
US5488145A (en) 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US5716950A (en) * 1994-01-14 1998-02-10 Nippon Shoji Kabushiki Kaisha Diazacycloalkanealkylsulfonamide derivatives
AU3275595A (en) 1994-08-05 1996-03-04 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
CA2196529A1 (en) 1994-08-08 1996-02-22 Peter Davies Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
US5466683A (en) 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
CA2210500A1 (en) 1995-01-16 1996-07-25 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound - fatty acid conjugates
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US5858326A (en) 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
AU6728396A (en) 1995-08-17 1997-03-12 Ontario Cancer Institute, The Protein fibril assembly assay
WO1997009445A1 (en) 1995-09-01 1997-03-13 Shapiro Howard K Methods and compositions for development of drug screening procedures and diagnostic tools
AU6887996A (en) 1995-09-01 1997-04-01 Washington University School Of Medicine Method of reducing neurotoxic injury with zinc chelators
EP1018877A4 (en) 1995-10-17 2000-08-09 Dovetail Technologies Inc LOW MOLECULAR WEIGHT STIMULANTS OF BONE MARROW AND IMMUNE SYSTEM CELLS
US5972956A (en) 1995-11-02 1999-10-26 Warner-Lambert Company Inhibition of amyloidosis by 9-acridinones
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AU703540B2 (en) 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US6043283A (en) 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
EP1005348A1 (en) 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US5989592A (en) 1996-10-03 1999-11-23 Coastside Bio Resources Inhibition of complement pathway by sea cucumber fractions
SE9604582D0 (sv) 1996-12-13 1996-12-13 Astra Ab Novel compounds
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
DE69842048D1 (de) 1997-08-01 2011-01-27 Max Planck Gesellschaft Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
US5869469A (en) 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
NZ550116A (en) 1997-08-18 2008-03-28 Neurochem Int Ltd Phosphono-carboxylate compounds for treating amyloidosis
DK1014996T3 (da) 1997-08-28 2003-09-29 Univ Washington Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
EP1051161B1 (en) 1998-01-28 2006-03-22 Warner-Lambert Company Llc Method for treating alzheimer's disease
CA2632106A1 (en) 1998-02-11 1999-08-19 Neurochem (International) Limited Method for modulating macrophage activation
US20020022657A1 (en) 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US6329356B1 (en) * 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
WO2000057707A1 (en) 1999-03-15 2000-10-05 Proteotech, Inc. Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
AU4013900A (en) 1999-03-19 2000-10-09 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
MXPA01010835A (es) 1999-04-28 2003-07-14 Univ Kingston Composiciones y metodos para tratar amiloidosis.
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
WO2001003680A2 (en) 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
WO2001085093A2 (en) 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
JP2003520253A (ja) 2000-01-19 2003-07-02 ジェンテリック， インコーポレーテッド 細胞に核酸をトランスフェクトする方法
US6376557B1 (en) 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
MXPA03008164A (es) 2001-03-13 2003-12-12 Univ Kingston Agentes anti-epileptogenos.
US7501429B2 (en) * 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
EP1397136A1 (en) * 2001-05-25 2004-03-17 Queen's University At Kingston Heterocyclic beta-aminoacids and their use as anti-epileptogenic agents
US20040006092A1 (en) * 2001-08-31 2004-01-08 Neurochem, Inc. Amidine derivatives for treating amyloidosis
US20030077833A1 (en) 2001-09-07 2003-04-24 Queen's University At Kingston Diagnositc methods for determining susceptibility to convulsive conditions
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
MXPA05013977A (es) 2003-06-23 2006-03-09 Neurochem Int Ltd Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
SI1646659T1 (sl) * 2003-06-23 2014-07-31 Kiacta Sarl Postopek za pripravo spojin 1,3-propan disulfonske kisline
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20080038192A1 (en) * 2004-07-19 2008-02-14 Neurochem Inc. Diagnostic Methods Of Multiple Organ Amyloidosis
EP1828111A2 (en) * 2004-11-12 2007-09-05 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
EP1817305A2 (en) * 2004-11-16 2007-08-15 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis

Also Published As

Publication number Publication date
EA019334B1 (ru) 2014-02-28
US20080015180A1 (en) 2008-01-17
IL172194A0 (en) 2011-08-01
TW200520752A (en) 2005-07-01
NZ579241A (en) 2010-10-29
US7244764B2 (en) 2007-07-17
IL172194A (en) 2014-04-30
TWI361686B (en) 2012-04-11
US20100190753A1 (en) 2010-07-29
US20050038117A1 (en) 2005-02-17
US7598269B2 (en) 2009-10-06
TW200600087A (en) 2006-01-01
CN101712640A (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200700225A1 (ru) Аналоги тетрапептида
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201691142A1 (ru) Ингибиторы мек и способы их применения
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20034056D0 (no) Proliferative sykdommer
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE507839T1 (de) Kombinationstherapie
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
EP1484066A4 (en) Remedy for infections
DE602004021568D1 (de) Thiadibenzoazulenderivate zur behandlung von entzündlichen erkrankungen
EP1691836A4 (en) ANTI-PECAM TREATMENT FOR REMOVAL OF METASTASIS
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY RU